Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
13.6M
-
Shares change
-
+2.38M
-
Total reported value, excl. options
-
$131M
-
Value change
-
+$22.2M
-
Put/Call ratio
-
0.99
-
Number of buys
-
50
-
Number of sells
-
-25
-
Price
-
$9.66
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2015
90 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2015.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.6M shares
of 236M outstanding shares and own 5.75% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3.27M shares), FMR LLC (1.97M shares), BlackRock Fund Advisors (1.02M shares), VANGUARD GROUP INC (614K shares), Visium Asset Management, LP (556K shares), BlackRock Institutional Trust Company, N.A. (546K shares), STIFEL FINANCIAL CORP (445K shares), Marshall Wace LLP (428K shares), BANK OF AMERICA CORP /DE/ (329K shares), and STATE STREET CORP (277K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.